Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer

References

• Jayson GC, Kohn EC, Kitchener HC. Ovarian cancer. Lancet. 2014;384:1376–1388.10.1016/S0140-6736(13)62146-7
   PubMed Web of Science ®Google Scholar
• Malaysian National Cancer Registry. Malaysian cancer statistics: data and figures. Putra Jaya (Malaysia): Ministry of Health; 2007. Available from:http://www.care.upm.edu.my/dokumen/13603_NCR2007.pdf. [ Cited 2016 Jun 4].
   Google Scholar
• Rosen DG, Yang G, Liu G, et al. Ovarian cancer: pathology, biology and disease models. Front. Biosci. 2010;14:2089–2102.
   Google Scholar
• Björkholm E, Pettersson F, Einhorn N, et al. Long-term follow-up and prognostic factors in ovarian carcinoma: the Radiumhemmet series 1958 to 1973. Acta Radiol.: Oncol. 1982;21:413–419.10.3109/02841868209134321
   PubMedGoogle Scholar
• Högberg T, Carstensen J, Simonsen E, et al. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol. Oncol. 1993;48:38–49.10.1006/gyno.1993.1007
   PubMed Web of Science ®Google Scholar
• Zhao L, Guo M, Sneige N, et al. Value of PAX8 and WT1 immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens. Am. J. Clin. Pathol. 2012;137:304–309.10.1309/AJCPU0FION3RKKFO
   PubMed Web of Science ®Google Scholar
• Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues. Appl. Immunohistochem. Mol. Morphol. 2011;19:293–299.10.1097/PAI.0b013e3182025f66
   PubMedGoogle Scholar
• Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109–115.10.1111/his.2004.44.issue-2
   PubMed Web of Science ®Google Scholar
• Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am. J. Surg. Pathol. 2011;35:816–826.10.1097/PAS.0b013e318216c112
   PubMed Web of Science ®Google Scholar
• Liliac L, Carcangiu ML, Canevari S, et al. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis. Rom. J. Morphol. Embryol. 2013;54:17–27.
   PubMed Web of Science ®Google Scholar
• Gessler M, Poustka AM, Cavenee W, et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature. 1990;343:774–778.10.1038/343774a0
   PubMed Web of Science ®Google Scholar
• McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420–432.10.1097/PAT.0b013e328348a6e7
   PubMed Web of Science ®Google Scholar
• Plachov D, Chowdhury K, Walther C, et al. PAX8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development. 1990;110:643–651.
   PubMed Web of Science ®Google Scholar
• Poleev A, Fickenscher H, Mundlos S, et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms’ tumors. Development. 1992;116:611–623.
   PubMed Web of Science ®Google Scholar
• Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, et al. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer. 2006;6:51. doi:10.1186/1471-2407-6-90
   PubMed Web of Science ®Google Scholar
• Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 2004;28:496–504.10.1097/00000478-200404000-00009
   PubMed Web of Science ®Google Scholar
• McCluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod. Pathol. 2015;28:1101–1122.10.1038/modpathol.2015.77
   PubMed Web of Science ®Google Scholar
• Devan SM, Pailoor J, Sthaneshwar P, et al. Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels. Asian Pac. J. Cancer Prev. 2013;14:4545–4548.10.7314/APJCP.2013.14.8.4545
   PubMedGoogle Scholar
• Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int. J. Gynecol. Pathol. 2000;19:158–163.10.1097/00004347-200004000-00010
   PubMed Web of Science ®Google Scholar
• McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int. J. Gynecol. Pathol. 2004;23:97–99.10.1097/00004347-200404000-00002
   PubMed Web of Science ®Google Scholar
• Kutanan W, Kitpipit T, Phetpeng S, et al. Forensic STR loci reveal common genetic ancestry of the Thai-Malay muslims and Thai Buddhists in the deep southern region of Thailand. J. Human Genet. 2014;59:675–681.10.1038/jhg.2014.93
   PubMed Web of Science ®Google Scholar
• O’Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology. 2007;50:773–779.10.1111/his.2007.50.issue-6
   PubMed Web of Science ®Google Scholar
• O’Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas. Significantly higher expression of p53, MIB1, bcl2, her-2/neu and C-KIT in high-grade neoplasms. Am. J. Surg. Pathol. 2005;29:1034–1041.
   PubMed Web of Science ®Google Scholar
• Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of k-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int. J. Gynecol. Pathol. 2003;22:37–41.10.1097/00004347-200301000-00009
   PubMed Web of Science ®Google Scholar
• Sieben NLG, Macropoulos P, Roemen GMJM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 2004;202:336–340.10.1002/(ISSN)1096-9896
   PubMed Web of Science ®Google Scholar
• Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma. Adv. Anat. Pathol. 2009;16:267–282.10.1097/PAP.0b013e3181b4fffa
   PubMed Web of Science ®Google Scholar
• Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 2006;108:361–368.10.1097/01.AOG.0000227787.24587.d1
   PubMed Web of Science ®Google Scholar